Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.
about
Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Are we ready for the 10% solution?Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinomaThe best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective studyNeo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise.Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Evaluation of cancer treatment in the abdomen: Trends and advances.Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).Quality of life and supportive care for patients with metastatic renal cell carcinoma.Neoadjuvant and adjuvant treatment of renal cell carcinoma.Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.Do targeted agents offer clinical benefit as presurgical therapy?Targeted therapy of kidney cancer: keeping the art around the algorithms.Cytoreductive nephrectomy: past, present and future.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.New challenges in kidney cancer management: integration of surgery and novel therapies.Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome.Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis receiving molecularly targeted therapies.Is there a role for neoadjuvant targeted therapy to downsize primary tumors for organ sparing strategies in renal cell carcinoma?Renal cell cancer: what can we learn from pre-operative studies?[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].Multimodal treatment of advanced renal cancer in 2017.Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
P2860
Q26783520-F35246BA-8284-47F6-801D-229798AF3C0FQ33577894-5C21AD71-AFB8-4F25-93FD-FD80419DAD58Q33740717-AE332AB1-D3ED-4652-9B46-64E575BD4663Q33745827-619678AA-6857-44D9-8CC1-5497D872B77BQ34880943-379BF539-D8AD-4707-9E2A-9148DF30FAC9Q35115559-4F2B593C-BADB-4E0C-924A-CDD752FAC4D8Q35918881-890A7501-3867-40EA-8B91-D455975ADCFDQ36084067-C0CB427D-F697-4619-BD1A-B0564E217261Q36197277-B9B7365F-FE51-4856-9C1D-FD6A15083EF6Q36832118-C9DF51E6-1FF8-4BB5-8DBC-44FC5506A070Q37385255-D9AEBFC2-1466-458E-9723-5A6C1FB894B7Q38017587-8E4063BC-F75A-46BD-95B3-6752087D632EQ38020243-BE8105AB-62A0-4751-BBB9-6C2C3E3B8622Q38020245-8DAB0D82-3727-4B19-82CD-5B91AFA713ACQ38084591-2FA43360-8F14-47BF-ABDC-3A93F8940F16Q38118060-D0A3E495-8535-4ADF-9274-554DB6049A63Q38176034-54D2513E-BF7B-47EE-A7D2-1E40612F40A4Q38196855-D175A461-70D5-4F60-9635-2A8FDBC741B7Q38202061-629BEAE2-0B1C-48E4-B8DD-40DC4977E2CBQ38381788-851F91A8-0B8B-4095-8DEF-FD737B66BEDFQ38487988-2BDC27C7-7D57-4BA7-B6FB-951008485C4CQ40663333-BC2F1A65-DE35-4A02-9199-D768D8FC5429Q40707127-3AE64225-FBF4-4299-81FA-A96C7271E099Q40754987-ACA337A0-E423-48E7-B770-4552C54466CBQ41162248-2477E9BF-B253-4547-9B44-8157B513F142Q41886782-3BBFAD0F-BF63-46BF-931E-E210285C231EQ42175050-B9ACC952-9D05-462F-9B2E-F70DB5F6D35DQ43810315-35381DB3-CEAE-42F3-84B7-257F9E2F852AQ47550490-C675C31C-2DDE-4CA1-AFDF-18098E7BF7B5Q50927948-D29AA450-1E98-439E-B750-B6B0853E7862
P2860
Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Early primary tumor size reduc ...... tients treated with sunitinib.
@ast
Early primary tumor size reduc ...... tients treated with sunitinib.
@en
type
label
Early primary tumor size reduc ...... tients treated with sunitinib.
@ast
Early primary tumor size reduc ...... tients treated with sunitinib.
@en
prefLabel
Early primary tumor size reduc ...... tients treated with sunitinib.
@ast
Early primary tumor size reduc ...... tients treated with sunitinib.
@en
P2093
P2860
P1433
P1476
Early primary tumor size reduc ...... tients treated with sunitinib.
@en
P2093
Christopher G Wood
E Jason Abel
Nizar M Tannir
Pheroze Tamboli
Stephen H Culp
Surena F Matin
P2860
P304
P356
10.1016/J.EURURO.2011.07.008
P407
P577
2011-07-14T00:00:00Z